Keros Therapeutics, Inc.
15.04-0.14 (-0.92%)
Oct 29, 4:00:02 PM EDT · NasdaqGM · KROS · USD
Key Stats
Market Cap
458.21MP/E (TTM)
47.00Basic EPS (TTM)
0.32Dividend Yield
0%Recent Filings
8-K
Keros launches $375M buyback
Keros Therapeutics struck deals on October 15, 2025, to repurchase all shares from ADAR1 Capital Management and Pontifax Venture Capital—totaling 10,176,595 shares at $17.75 each for about $181 million—while Pontifax directors Tomer Kariv and Ran Nussbaum resigned immediately. This advances the company's $375 million capital return plan, with a tender offer for up to $194 million more shares slated by October's end, funded by $693.5 million in cash as of September 30. Board streamlined. Yet risks linger in clinical timelines.
8-K
KER-065 Phase 1 data presented
Keros Therapeutics unveiled additional Phase 1 data for KER-065 at the ASBMR 2025 meeting on September 6, showing the drug was well-tolerated in healthy males with no serious adverse events. It boosted bone formation, cut resorption, and sustained whole-body and lumbar spine BMD gains through Day 141 post-dosing. This bolsters KER-065's promise for DMD, where bone loss hits hard from muscle weakness and steroids. Data highlight sustained effects.
8-K
CEO conference appearances announced
Keros Therapeutics announced CEO Jasbir Seehra's upcoming talks at the 2025 Wells Fargo Healthcare Conference on September 4 and the H.C. Wainwright Global Investment Conference on September 9. These fireside chat and corporate presentation offer investors fresh insights into the company's TGF-β-focused pipeline, including elritercept for cytopenias and KER-065 for Duchenne muscular dystrophy. Replays available for 90 days. Visibility boosts amid clinical progress.
8-K
FDA grants KER-065 orphan status
Keros Therapeutics scored FDA Orphan Drug designation for KER-065 on August 20, 2025, targeting Duchenne muscular dystrophy, a rare muscle-wasting disease affecting fewer than 200,000 in the US. This milestone unlocks tax credits, fee waivers, and seven years of market exclusivity upon approval, while the company pushes into a Phase 2 trial. Orphan status spotlights DMD's unmet needs. Yet clinical risks loom large.
8-K
Keros streamlines for KER-065 focus
Keros Therapeutics announced a strategic realignment on August 6, 2025, discontinuing cibotercept development after its PAH trial flop while prioritizing KER-065 for Duchenne muscular dystrophy, backed by Phase 1 data showing muscle gains and fat loss. Leadership shifts include promoting Lorena Lerner to Chief Scientific Officer, parting with COO Christopher Rovaldi effective August 18, and appointing Jean-Jacques Bienaimé as board chair. This leaner structure sharpens focus on KER-065's Phase 2 launch in Q1 2026. Transitions signal efficiency.
AKRO
Akero Therapeutics, Inc.
54.00+0.00
CERO
CERo Therapeutics Holdings, Inc
1.79-0.09
ELVN
Enliven Therapeutics, Inc.
22.65+1.10
EWTX
Edgewise Therapeutics, Inc.
16.33-0.09
GTBP
GT Biopharma, Inc.
0.60-0.07
KAPA
Kairos Pharma, Ltd.
1.10-0.04
KRRO
Korro Bio, Inc.
38.78-1.29
KZR
Kezar Life Sciences, Inc.
6.15-0.10
OMER
Omeros Corporation
7.68-0.28
XERS
Xeris Biopharma Holdings, Inc.
9.62+0.39